powered by

DSK Legal Advises HealthQuad Fund II In Its Investment In Beta Drugs Limited

Deal Makers

DSK Legal represented and advised HealthQuad Fund II in its investment in Beta Drugs Limited, a listed entity, through the subscription of equity shares and compulsory convertible debentures. Other investors participating in this funding round included Inti Capital VCC – Inti Capital I and Generational Capital Breakout Fund 1.

Beta Drugs is engaged in the manufacturing, distribution, and sale of pharmaceutical products across domestic and international markets, specialising in oncology-focused formulations.

DSK Legal’s Team comprised Partner Nakul Batra,  Principal Associate Palak Sehgal, Senior Associate Singh, Associates Aankhi Anwesha and Daksh Krishnan.

Source: DSK Legal’s LinkedIn Page

The deal reporting on this platform is based on the information received from law firms, and therefore, some details may be missing/incomplete. If your firm has not been credited for this deal, write to us at admin@thedealmatter.com mentioning your firm’s name, lawyers involved (including designation) and client represented.

Featured Deals

Closed a deal?

Publish it on TDM

Subscribe to our Newsletter